Cardiovascular Diseases E-Book

Y. Robert Li

• Herausgeber: John Wiley & Sons
• Kategorie: Fachliteratur
• Sprache: Englisch

Seitenzahl: 1406

Veröffentlichungsjahr: 2015

Beschreibung

Written in an accessible style and consistent format, the book covers both the fundamentals and advances in the pharmacology of cardiovascular drugs, as well as their integrated applications in the management of individual cardiovascular diseases. * Integrates fundamentals and recent advances regarding cardiovascular drugs, blending basic and clinical sciences needed to effectively understand and treat cardiovascular diseases * Facilitates understanding of drug action and mechanism by covering physiology / pathophysiology and pharmacology * Includes guidelines and algorithms for pharmacotherapeutic management of cardiovascular diseases * Uses case presentations and study questions to enhance understanding of the material * Serves as a resource for pharmaceutical and medical students and researchers interested in cardiovascular issues

Leseprobe

CONTENTS

Cover

Title page

Preface

List of Abbreviations

Unit I: General Introduction

1 Introduction to Cardiovascular Diseases

1.1 Overview

1.2 Definition of Cardiovascular Diseases

1.3 Classification of Cardiovascular Diseases

1.4 Prevalence, Incidence, and Trend of Cardiovascular Diseases

1.5 Risk Factors of Cardiovascular Diseases

1.6 Prevention and Control of Cardiovascular Diseases

1.7 Cardiovascular Risk Prediction and Evidence-based Treatments

1.8 Summary of Chapter Key Points

1.9 Self-Assessment Questions

References

2 Introduction to Principles of Pharmacology

2.1 Overview

2.2 Definitions and History

2.3 Pharmacological Paradigm: the Central Dogma in Pharmacology

2.4 Principles of Drug Discovery, Development, and Regulation

2.5 Pharmacology Subspecialties

2.6 Introduction to Cardiovascular Pharmacology

2.7 Summary of Chapter Key Points

2.8 Self-Assessment Questions

References

Unit II: Dyslipidemias

3 Overview of Dyslipidemias and Drug Therapy

3.1 Introduction

3.2 Lipoprotein Metabolism

3.3 Dyslipidemias and Genetic Lipoprotein Disorders

3.4 Mechanistically Based Drug Therapy of Dyslipidemias

3.5 Summary of Chapter Key Points

3.6 Self-Assessment Questions

References

4 Drugs for Dyslipidemias

4.1 Overview

4.2 Statins

4.3 Bile Acid Sequestrants

4.4 Cholesterol Absorption Inhibitors

4.5 Fibrates

4.6 Niacin

4.7 New Drugs for HoFH

4.8 Phytosterols and Phytostanols

4.9 Omega-3 Fatty Acids

4.10 Emerging Therapeutic Modalities for Dyslipidemias

4.11 Summary of Chapter Key Points

4.12 Self-Assessment Questions

References

5 Management of Dyslipidemias: Principles and Guidelines

5.1 Overview

5.2 General Principles of the Management of Dyslipidemias

5.3 Current Evidence-Based Guidelines on the Management of Dyslipidemias

5.4 Summary of Chapter Key Points

5.5 Self-Assessment Questions

References

Unit III: Hypertension and Multitasking Cardiovascular Drugs

6 Overview of Hypertension and Drug Therapy

6.1 Introduction

6.2 Definitions, Classifications, and Epidemiology of Hypertension

6.3 Pathophysiology of Hypertension

6.4 Mechanistically Based Drug Therapy of Hypertension: An Overview

6.5 Summary of Chapter Key Points

6.6 Self-Assessment Questions

References

7 Diuretics

7.1 Overview

7.2 Volume Regulation and Drug Targeting

7.3 Thiazide and Thiazide-Type Diuretics

7.4 Loop Diuretics

7.5 Potassium-Sparing Diuretics

7.6 Other Diuretics

7.7 Summary of Chapter Key Points

7.8 Self-Assessment Questions

References

8 Sympatholytics

8.1 Overview

8.2 Sympathetic Nervous System and Drug Targeting

8.3 α-Adrenergic Receptor Antagonists

8.4 β-Adrenergic Receptor Antagonists

8.5 Centrally Acting Sympatholytics

8.6 Summary of Chapter Key Points

8.7 Self-Assessment Questions

References

9 Inhibitors of the Renin–Angiotensin–Aldosterone System

9.1 Overview

9.2 The Raas and Drug Targeting

9.3 Direct Renin Inhibitors

9.4 ACE Inhibitors

9.5 ARBs

9.6 Comparative Pharmacology of Direct Renin Inhibitors, Ace Inhibitors, and Arbs

9.7 Summary of Chapter Key Points

9.8 Self-Assessment Questions

References

10 Calcium channel blockers

10.1 Overview

10.2 Calcium Channels and Drug Targeting